Quebec City, Quebec, April 3, 2018 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) announces that the integration of Opsens’ technology, within the Impella Cardiac Pump® (“Impella CP®“), marketed by its client Abiomed, Inc. (” Abiomed “), is approved by the US Food and Drug Administration (” FDA “).
This news follows the US$6 million cooperation and development agreement signed in April 2014. As part of this agreement, Opsens had granted Abiomed an exclusive worldwide license to include its miniature pressure sensor in circulatory assist devices. This approval released a new milestone payment of US$500,000 to Opsens.
Opsens is proud to collaborate with Abiomed in this project, “We are pleased to see our technologies used in highly recognized applications such as the Impella platform in cardiology,” said Louis Laflamme, President and CEO of Opsens.
The granting of this license to Abiomed is part of Opsens’ strategy to capitalize on the development of its sensor by offering select partners the rights to exploit sensors in specific areas while focusing on the Company’s products for the Fractional Flow Reserve (“FFR”) market.
Opsens focuses mainly on the measure of FFR in interventional cardiology. Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.
About ABIOMED, Inc. (www.abiomed.com)
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Their products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333
Robin Villeneuve, CPA, CA Chief Financial Officer, 418.781.0333